The rapid spread of the coronavirus disease 2019 (COVID-19) pandemic called for a rapid response from the scientific community, sparking an unprecedented wave of research and publications ([@bib0007]). Journals fast tracked peer review, and publishers waived publication fees and provided free access to articles' content. The preprint model has been pushed forward carrying both pro and con arguments ([@bib0003]). To date, more than 10,000 COVID-19 papers have been indexed in PubMed, with an average more than 100 new papers indexed every day.

To support our hospital teams and regional health authorities, we have coordinated the "COVID-19 Literature Task Force" which has, on a daily basis, systematically retrieved and critically assessed all PubMed indexed papers on "COVID-19 and mental health".

Four hundred and fifteen papers on "COVID-19 and mental health" were identified from 20th January to 17th May, with on average nearly four new papers indexed on PubMed every day. About one fifth of COVID-19 mental health papers were published in China (22.9%) and in the US (21.3%) respectively, followed by India (7.7%), the UK (7.7%), and Italy (5.3%). Unsurprisingly, the largest amount of papers (78.1%) were opinion papers; 3% were reviews. Only one fifth (18.8%) were original studies, of which the majority (85.8%) cross-sectional.

The impact of COVID-19 on mental health was mostly investigated in the general population (26%), and to a lesser extent in vulnerable groups including healthcare workers (14%), psychiatric patients (7.2%), children and adolescents (3.9%), and older subjects (2.9%). Similarly, the impact of lockdown restrictions on mental health was mainly evaluated in the general population (5.5%), compared to psychiatric patients and older individuals (0.2%, respectively). Thirty-four studies (8.2%) investigated COVID-19 impact on social, addiction and psychiatric services, and 6.6% of selected papers examined the potential role of telepsychiatry in promoting continuity of care at the community-level. Thirty studies (7.2%) focused on suitable psychological interventions for the general population in order to help with loneliness, hopelessness, and death anxiety exacerbated during health emergencies, along with the effects of associated social distancing measures.

In March 2020, in the first weeks of the pandemic in the UK, an expert panel convened by the UK Academy of Medical Sciences and a mental health research charity (MQ: Transforming Mental Health) explored the psychological, social, and neuroscientific effects of COVID-19 and set out immediate priorities and longer-term strategies for mental health science research ([@bib0001]).

The immediate priority is the collection of high-quality data on the mental health and psychological effects of the COVID-19 pandemic across the whole population and specific vulnerable groups (including subjects with pre-existing mental or physical health issues, children and adolescents, older persons, and socially excluded groups) ([@bib0005]). Another priority is to assess the effects of COVID-19 on brain function, neurocognition, and mental health in all clinical stages of infection and illness.

There is an urgent need to improve and develop psychological interventions for healthcare staff and the general population, and promote continuity of care for psychiatric patients at the community-level through online psychotherapies and other telemental health services as well.

Longer-term strategies that are needed include attention to the range of psychiatric consequences that may depend on the COVID-19 pandemic, the associated national quarantines, and the worldwide economic decline that occurred, respectively. Importantly, there is an association between increasing unemployment rates, more depressive morbidity and higher suicide rates ([@bib0002]). Such effects of economic crisis in the past, as in 2008, or 1990s, may be exacerbated in the coming years if the COVD-19 pandemic is not controlled completely. For instance, if national quarantines are eased in the coming months, but then COVID-19 rates begin to rise, any temporary economic recovery may be erased by a later repeated partial or complete national quarantine. If such recrudescence of infection occurs in the fall of 2020 and/or winter/spring of 2021, economic harms may return a year from now, along with higher rates of unemployment, and consequent worsened psychiatric morbidity in the general population ([@bib0004]).

The psychiatric harms of COVID-19 among healthcare workers, such as post-traumatic stress disorder, may be difficult to manage if there will be repeated infection spikes and repeated periods of morbidity and mortality in the general population. Such repeated traumas will make it difficult, for healthcare workers, to manage and recover from past traumatic experiences during the pandemic.

In short, at the peak of the COVID-19 pandemic rise in the last few months, the medical need was for emergency and intensive care unit services, especially for respiratory care. In the coming months at least, and hopefully not years, the medical need will be for psychiatric services, not only for those who suffered from COVID-19 infection, and not only for those who are at risk for infection, but also for those who have cared for the sick and dying, and those who will be called on to continuatively provide such care and consolation.

In conclusion, high-quality original data on the mental health and psychological effects of the COVID-19 pandemic is urgently needed ([@bib0006]). The focus of medical attention in the COVID-19 pandemic should expand from the essential search for a vaccine and testing of anti-viral treatments to the equally essential need to help patients, the general population, and healthcare workers to take care of their own psychological well-being.
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